Gabriel Mak

443 total citations
20 papers, 288 citations indexed

About

Gabriel Mak is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gabriel Mak has authored 20 papers receiving a total of 288 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 6 papers in Surgery and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gabriel Mak's work include Lung Cancer Treatments and Mutations (4 papers), Neuroendocrine Tumor Research Advances (3 papers) and Lung Cancer Research Studies (3 papers). Gabriel Mak is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Neuroendocrine Tumor Research Advances (3 papers) and Lung Cancer Research Studies (3 papers). Gabriel Mak collaborates with scholars based in United Kingdom, United States and Australia. Gabriel Mak's co-authors include Hendrik‐Tobias Arkenau, Michele Moschetta, Mario Uccello, Martin Förster, Melvin Chin, Stergios Boussios, Jean‐Charles Soria, Suresh Senan, Benjamin Kasenda and Norah J. Shire and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Gabriel Mak

20 papers receiving 284 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gabriel Mak United Kingdom 10 200 100 72 43 41 20 288
Federica Guzzo Italy 12 112 0.6× 76 0.8× 38 0.5× 67 1.6× 24 0.6× 30 348
María González Cao Spain 12 207 1.0× 144 1.4× 107 1.5× 29 0.7× 28 0.7× 38 336
Rebecca Pharaon United States 10 210 1.1× 181 1.8× 166 2.3× 19 0.4× 23 0.6× 27 408
Hiroaki Furuyama Japan 8 107 0.5× 100 1.0× 46 0.6× 97 2.3× 52 1.3× 23 295
Jingquan Jia United States 10 114 0.6× 116 1.2× 58 0.8× 21 0.5× 13 0.3× 28 246
Shinya Ohara Japan 12 159 0.8× 115 1.1× 152 2.1× 135 3.1× 37 0.9× 29 376
Kate Moodie Australia 7 159 0.8× 89 0.9× 108 1.5× 57 1.3× 10 0.2× 15 295
Jodi A. McKenzie United States 8 121 0.6× 155 1.6× 73 1.0× 21 0.5× 18 0.4× 30 302
Youya Nakazawa Japan 8 233 1.2× 161 1.6× 45 0.6× 98 2.3× 13 0.3× 10 372
Maribel Mármol Spain 8 175 0.9× 90 0.9× 29 0.4× 34 0.8× 65 1.6× 8 278

Countries citing papers authored by Gabriel Mak

Since Specialization
Citations

This map shows the geographic impact of Gabriel Mak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriel Mak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriel Mak more than expected).

Fields of papers citing papers by Gabriel Mak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gabriel Mak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriel Mak. The network helps show where Gabriel Mak may publish in the future.

Co-authorship network of co-authors of Gabriel Mak

This figure shows the co-authorship network connecting the top 25 collaborators of Gabriel Mak. A scholar is included among the top collaborators of Gabriel Mak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabriel Mak. Gabriel Mak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Mak, Gabriel, et al.. (2024). Primary squamous cell carcinoma of the prostate. BMJ Case Reports. 17(11). e262520–e262520. 1 indexed citations
3.
Papadopoulos, K., Débora S. Bruno, Satoru Kitazono, et al.. (2023). OA05.06 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab ± Carboplatin in Advanced/mNSCLC: Initial Results from Phase 1b TROPION-Lung04. Journal of Thoracic Oncology. 18(11). S55–S55. 7 indexed citations
4.
Borghaei, Hossein, Saiama N. Waqar, Débora S. Bruno, et al.. (2023). TROPION-Lung04: Phase 1b, multicenter study of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy ± carboplatin in advanced/metastatic non-small cell lung cancer (mNSCLC).. Journal of Clinical Oncology. 41(16_suppl). TPS3158–TPS3158. 10 indexed citations
5.
Mak, Gabriel, Jean‐Charles Soria, Sarah P. Blagden, et al.. (2019). A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. British Journal of Cancer. 120(10). 975–981. 69 indexed citations
6.
7.
Senan, Suresh, Norah J. Shire, Gabriel Mak, W. Yao, & Haiyi Jiang. (2019). ADRIATIC: A phase III trial of durvalumab ± tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer. Annals of Oncology. 30. ii25–ii25. 8 indexed citations
8.
Arkenau, Hendrik‐Tobias, Antoîne Italiano, Gabriel Mak, et al.. (2018). An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. European Journal of Cancer. 103. 17–23. 10 indexed citations
9.
Uccello, Mario, et al.. (2018). Towards an Optimal Treatment Algorithm for Metastatic Pancreatic Ductal Adenocarcinoma (PDA). Current Oncology. 25(1). 90–94. 9 indexed citations
10.
Moschetta, Michele, et al.. (2017). Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer. Experimental Hematology and Oncology. 6(1). 1–1. 9 indexed citations
11.
Goyal, Lipika, Hendrik-Tobias Arkenau, Ben Tran, et al.. (2017). Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma. Annals of Oncology. 28. iii145–iii145. 18 indexed citations
12.
Moschetta, Michele, Mario Uccello, Benjamin Kasenda, et al.. (2017). Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade. BioMed Research International. 2017. 1–5. 49 indexed citations
13.
Nebot, Noelia, Hendrik‐Tobias Arkenau, Jeffrey R. Infante, et al.. (2017). Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600–mutant tumours. British Journal of Clinical Pharmacology. 84(4). 764–775. 12 indexed citations
14.
Moschetta, Michele, Benjamin Kasenda, Gabriel Mak, et al.. (2016). Dynamics of neutrophil to lymphocyte ratio (NLR) predict effectiveness of PD1/PDL1 inhibition. Annals of Oncology. 27. vi24–vi24. 2 indexed citations
15.
He, Emily, Nicholas J. Hawkins, Gabriel Mak, et al.. (2016). The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study. The Oncologist. 21(5). 618–625. 12 indexed citations
16.
Arkenau, Hendrik‐Tobias, Anas Gazzah, Ruth Plummer, et al.. (2015). A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors.. Journal of Clinical Oncology. 33(15_suppl). 2593–2593. 4 indexed citations
17.
Mak, Gabriel, Hendrik‐Tobias Arkenau, & Melvin Chin. (2014). Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment. Melanoma Research. 24(4). 408–412. 7 indexed citations
18.
Mak, Gabriel, Melvin Chin, Najmun Nahar, & Paul de Souza. (2014). Cutaneous metastasis of prostate carcinoma treated with radiotherapy: a case presentation. BMC Research Notes. 7(1). 505–505. 12 indexed citations
19.
Mak, Gabriel, et al.. (2014). Use of neostigmine in capecitabine-induced paralytic ileus.. PubMed. 99(5). e225–8. 1 indexed citations
20.
Mak, Gabriel, et al.. (2013). Use of neostigmine in capecitabine-induced paralytic ileus. Tumori Journal. 99(5). e225–e228. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Federica Guzzo Breakdown of academic impact, for papers by María González Cao Breakdown of academic impact, for papers by Rebecca Pharaon Breakdown of academic impact, for papers by Hiroaki Furuyama Breakdown of academic impact, for papers by Jingquan Jia Breakdown of academic impact, for papers by Shinya Ohara Breakdown of academic impact, for papers by Kate Moodie Breakdown of academic impact, for papers by Jodi A. McKenzie Breakdown of academic impact, for papers by Youya Nakazawa Breakdown of academic impact, for papers by Maribel Mármol
Rankless by CCL
2026